Edwards Lifesciences Co. (NYSE:EW) VP Donald E. Bobo, Jr. Sells 9,500 Shares of Stock

Edwards Lifesciences Co. (NYSE:EW) VP Donald E. Bobo, Jr. sold 9,500 shares of the business’s stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $67.96, for a total transaction of $645,620.00. Following the completion of the transaction, the vice president now owns 46,936 shares in the company, valued at $3,189,770.56. The trade was a 16.83 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Edwards Lifesciences Trading Down 0.9 %

Shares of NYSE:EW opened at $67.92 on Friday. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The company’s 50 day moving average is $71.83 and its two-hundred day moving average is $70.32. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The company has a market cap of $39.93 billion, a PE ratio of 9.74, a P/E/G ratio of 4.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Equities analysts predict that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on EW shares. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and boosted their target price for the company from $82.00 to $90.00 in a report on Monday, December 16th. Royal Bank of Canada reissued an “outperform” rating and issued a $85.00 price target on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. The Goldman Sachs Group boosted their price target on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, December 5th. Stifel Nicolaus raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and boosted their price target for the company from $75.00 to $90.00 in a research note on Thursday, January 30th. Finally, Canaccord Genuity Group boosted their price target on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the company a “hold” rating in a research note on Thursday, February 13th. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $79.95.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Prosperity Consulting Group LLC boosted its holdings in shares of Edwards Lifesciences by 3.6% in the 4th quarter. Prosperity Consulting Group LLC now owns 3,906 shares of the medical research company’s stock valued at $289,000 after buying an additional 134 shares in the last quarter. Abacus Planning Group Inc. boosted its stake in Edwards Lifesciences by 0.3% during the 4th quarter. Abacus Planning Group Inc. now owns 40,207 shares of the medical research company’s stock worth $2,977,000 after purchasing an additional 140 shares during the period. Bowman & Co S.C. boosted its stake in Edwards Lifesciences by 1.2% during the 4th quarter. Bowman & Co S.C. now owns 12,487 shares of the medical research company’s stock worth $924,000 after purchasing an additional 148 shares during the period. Moors & Cabot Inc. boosted its stake in Edwards Lifesciences by 0.3% during the 4th quarter. Moors & Cabot Inc. now owns 54,589 shares of the medical research company’s stock worth $4,041,000 after purchasing an additional 152 shares during the period. Finally, Quadrant Capital Group LLC boosted its stake in Edwards Lifesciences by 3.1% during the 4th quarter. Quadrant Capital Group LLC now owns 5,180 shares of the medical research company’s stock worth $383,000 after purchasing an additional 156 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.